EMA Authorised: Opzelura (ruxolitinib phosphate) — Incyte Biosciences Distribution B.V.

View source ↗

Summary

The European Medicines Agency authorised Opzelura (ruxolitinib phosphate) for the treatment of vitiligo, with decision dated 26 February 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• Opzelura (ruxolitinib)

Snippet

Status: Authorised. Therapeutic area: Vitiligo. MAH: Incyte Biosciences Distribution B.V.. Decision date: 26/02/2026